The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: Comparison of pravastatin and atorvastatin

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 374, Issue 3, 2006, Pages 195-206

  Rakotoniaina, Zo ^a   Guerard, Pascal ^a   Lirussi, Frederic ^a   Goirand, Françoise ^a   Rochette, Luc ^a   Dumas, Monique ^a   Bardou, Marc ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Atorvastatin; Pravastatin; Pulmonary arterial hypertension; Reductase inhibitors

Indexed keywords

ACETYLCHOLINE; ATORVASTATIN; CASPASE 3; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MONOCROTALINE; NITROPRUSSIDE SODIUM; PRAVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DILATATION; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFECT; ENZYME DEGRADATION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HEART VENTRICLE SEPTUM; LUNG; MALE; NONHUMAN; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; RAT STRAIN; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

ACETYLCHOLINE; ANIMALS; APOPTOSIS; CASPASE 3; ENDOTHELIAL CELLS; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION, PULMONARY; LUNG; MALE; MONOCROTALINE; NITRIC OXIDE SYNTHASE TYPE III; NITROPRUSSIDE; PRAVASTATIN; PULMONARY ARTERY; PYRROLES; RATS; RATS, WISTAR; VENTRICULAR PRESSURE;

EID: 33751415352     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-006-0112-z     Document Type: Article

References (52)

1. Baetta R, Donetti E, Comparato C, Calore M, Rossi A, Teruzzi C, Paoletti R, Fumagalli R, Soma MR (1997) Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells. Pharmacol Res 36:115-121
2. Bardou M, Goirand F, Marchand S, Rouget C, Devillier P, Dumas JP, Morcillo EJ, Rochette L, Dumas M (2001) Hypoxic vasoconstriction of rat main pulmonary artery: role of endogenous nitric oxide, potassium channels, and phosphodiesterase inhibition. J Cardiovasc Pharmacol 38:325-334
3. Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, Naeije R, Galie N (2006) Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 47:2049-2056
4. Campian ME, Hardziyenka M, Michel MC, Tan HL (2006) How valid are animal models to evaluate treatments for pulmonary hypertension? Naunyn Schmiedebergs Arch Pharmacol 373 (6):391-400
5. Dobrucki LW, Kalinowski L, Dobrucki IT, Malinski T (2001) Statin-stimulated nitric oxide release from endothelium. Med Sci Monit 7:622-627
6. Ecarnot-Laubriet A, Assem M, Poirson-Bichat F, Moisant M, Bernard C, Lecour S, Solary E, Rochette L, Teyssier JR (2002) Stage-dependent activation of cell cycle and apoptosis mechanisms in the right ventricle by pressure overload. Biochim Biophys Acta 1586:233-242
7. Ecarnot-Laubriet A, Rochette L, Vergely C, Sicard P, Teyssier JR (2003) The activation pattern of the antioxidant enzymes in the right ventricle of rat in response to pressure overload is of heart failure type. Heart Dis 5:308-312
8. Endo H, Tanaka S, Sakai M (2004) Collagen diseases with pulmonary hypertension. Nihon Rinsho Meneki Gakkai Kaishi 27:127-136
9. Girgis RE, Li D, Zhan X, Garcia JG, Tuder RM, Hassoun PM, Johns RA (2003) Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol 285:H938-H945
10. Guerard P, Rakotoniaina Z, Goirand F, Rochette L, Dumas M, Lirussi F, Bardou M (2006) The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS. Naunyn Schmiedebergs Arch Pharmacol 373(6)401-414
11. Hatanaka T (2000) Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet 39:397-412
12. Hongo M, Mawatari E, Sakai A, Ruan Z, Koizumi T, Terasawa F, Yazaki Y, Kinoshita O, Ikeda U, Shibamoto T (2005) Effects of nicorandil on monocrotaline-induced pulmonary arterial hypertension in rats. J Cardiovasc Pharmacol 46:452-458
13. Ishikawa M, Namiki A, Kubota T, Yajima S, Fukazawa M, Moroi M, Sugi K (2006) Effect of pravastatin and atorvastatin on glucose metabolism in nondiabetic patients with hypercholesterolemia. Intern Med 45:51-55
14. Jain MK, Ridker PM (2005) Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 4:977-987
15. Jones PL, Rabinovitch M (1996) Tenascin-C is induced with progressive pulmonary vascular disease in rats and is functionally related to increased smooth muscle cell proliferation. Circ Res 79:1131-1142
16. Joyce M, Kelly CJ, Chen G, Bouchier-Hayes DJ (2001) Pravastatin attenuates lower torso ischaemia-reperfusion-induced lung injury by upregulating constitutive endothelial nitric oxide synthase. Eur J Vasc Endovasc Surg 21:295-300
17. Kaneta S, Satoh K, Kano S, Kanda M, Ichihara K (2003) All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells. Atherosclerosis 170:237-243
18. Kanno S, Wu YJ, Lee PC, Billiar TR, Ho C (2001) Angiotensin-converting enzyme inhibitor preserves p21 and endothelial nitric oxide synthase expression in monocrotaline-induced pulmonary arterial hypertension in rats. Circulation 104:945-950
19. Kao PN (2005) Simvastatin treatment of pulmonary hypertension: an observational case series. Chest 127:1446-1452
20. Kinlay S (2005) Potential vascular benefits of statins. Am J Med 118 Suppl 12A 62-67
21. Knapp AC, Huang J, Starling G, Kiener PA (2000) Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. Atherosclerosis 152:217-227
22. Koh KK (2000) Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 47:648-657
23. Kubota T, Fujisaki K, Itoh Y, Yano T, Sendo T, Oishi R (2004) Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors. Biochem Pharmacol 67:2175-2186
24. Laemmli UK, Beguin F, Gujer-Kellenberger G (1970) A factor preventing the major head protein of bacteriophage T4 from random aggregation. J Mol Biol 47:69-85
25. Laufs U, Liao JK (2000) Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med 10:143-148
26. Laufs U, La Fata V, Plutzky J, Liao JK (1998) Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97:1129-1135
27. Mach F, Senouf D, Fontana P, Boehlen F, Reber G, Daali Y, de Moerloose P, Sigwart U (2005) Not all statins interfere with clopidogrel during antiplatelet therapy. Eur J Clin Invest 35:476-481
28. Martin KB, Klinger JR, Rounds SI (2006) Pulmonary arterial hypertension: new insights and new hope. Respirology 11:6-17
29. Mason RP, Walter MF, Day CA, Jacob RF (2005) Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol 96:11F-23F
30. Nagashima H, Kasanuki H (2005). The status of lipid management in 1,836 patients with coronary artery disease: a multicenter survey to evaluate the percentage of Japanese coronary artery disease patients achieving the target low-density lipoprotein cholesterol level specified by the Japan Atherosclerosis Society. J Atheroscler Thromb 12:338-342
31. Nishimura T, Faul JL, Berry GJ, Vaszar LT, Qiu D, Pearl RG, Kao PN (2002) Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 166:1403-1408
32. Nishimura T, Vaszar LT, Faul JL, Zhao G, Berry GJ, Shi L, Qiu D, Benson G, Pearl RG, Kao PN (2003) Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 108:1640-1645
33. Pan TL, Thumboo J, Boey ML (2000) Primary and secondary pulmonary hypertension in systemic lupus erythematosus. Lupus 9:338-342
34. Parker RA, Huang Q, Tesfamariam B (2003) Influence of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculature. Atherosclerosis 169:19-29
35. Provencher S, Sitbon O, Humbert M, Cabrol S, Jais X, Simonneau G (2006) Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 27:589-595
36. Puikuan K, Chunyu Z, Jin F, Chaoshu T, Junbao D (2006) Inhalation of nebulized nitroglycerin, a nitric oxide donor, for the treatment of pulmonary hypertension induced by high pulmonary blood flow. Heart Vessels 21:169-179
37. Rinckel LA, Faris SL, Hitt ND, Kleinberg ME (1999) Rac1 disrupts p67phox/p40phox binding: a novel role for Rac in NADPH oxidase activation. Biochem Biophys Res Commun 263:118-122
38. Rosenson RS (2001) Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy. Am J Cardiovasc Drugs 1:411-420
39. Sanchez O, Sitbon O, Garcia G, Jais X, Simonneau G, Humbert M (2003) Pulmonary artery hypertension associated with connective tissue diseases. Presse Med 32:789-799
40. Shah DI, Singh M (2006) Effect of bis(maltolato) oxovanadium on experimental vascular endothelial dysfunction. Naunyn Schmiedebergs Arch Pharmacol 373:221-229
41. Singh TP, Rohit M, Grover A, Malhotra S, Vijayvergiya R (2006) A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 151(851):e1-e5
42. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, Kitakaze M, Liao JK (2001) Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 108:1429-1437
43. Taneva E, Borucki K, Wiens L, Makarova R, Schmidt-Lucke C, Luley C, Westphal S (2006) Early effects on endothelial function of atorvastatin 40 mg twice daily and its withdrawal. Am J Cardiol 97:1002-1006
44. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, Cool C, Wood K, Tuder RM, Burns N, Kasper M, Voelkel NF (2006) Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 291:L668-L676
45. Thomas HC, Lame MW, Dunston SK, Segall HJ, Wilson DW (1998) Monocrotaline pyrrole induces apoptosis in pulmonary artery endothelial cells. Toxicol Appl Pharmacol 151:236-244
46. Trad S, Amoura Z, Beigelman C, Haroche J, Costedoat N, Boutin le TH, Cacoub P, Frances C, Wechsler B, Grenier P, Piette JC (2006) Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 54:184-191
47. Van Ganse E, Laforest L, Alemao E, Davies G, Gutkin S, Yin D (2005) Lipid-modifying therapy and attainment of cholesterol goals in Europe: the return on expenditure achieved for lipid therapy (REALITY) study. Curr Med Res Opin 21:1389-1399
48. Vegh J, Soos G, Csipo I, Demeter N, Ben T, Dezso B, Zeher M, Devenyi K, Gaal J, Szegedi G, Bodolay E (2006) Pulmonary arterial hypertension in mixed connective tissue disease: successful treatment with Iloprost. Rheumatol Int 26:264-269
49. Wassmann S, Laufs U, Baumer AT, Muller K, Konkol C, Sauer H, Bohm M, Nickenig G (2001) Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 59:646-654
50. Weitz-Schmidt G (2002) Statins as anti-inflammatory agents. Trends Pharmacol Sci 23:482-486
51. Wright DG, Lefer DJ (2005) Statin mediated protection of the ischemic myocardium. Vascul Pharmacol 42:265-270
52. Zhou Z, Rahme E, Pilote L (2006) Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J 151:273-281